Skip to content

Protease inhibitor monotherapy in African setting results in viral load, but not CD4, failure in the short term

Darunavir working well for highly treatment-experienced patients in Switzerland

Switch from efavirenz or AZT associated with improvement in vitamin D levels

Adding drugs to already successful HIV treatment doesn't reduce viral load further

Targeted viral load tests in India prevent switches to second-line ARVs for one in four

Switch to nevirapine can happen at any CD4 count, says European drug regulator

Protease inhibitor to raltegravir switch maintains viral suppression, but NRTI resistance lowers efficacy

Maraviroc potentially useful if neurological disease is present

Laboratory monitoring of ART could be cost-effective for many countries